Aurobindo Pharma has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Extended Phenytoin Sodium Capsules USP, 100mg (ANDA 204309). The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Dilantin of Parke-Davis Division of Pfizer Inc.
Phenytoin Sodium Extended Capsules is an anti-epileptic product and indicated for the control of seizures and prevention and treatment of seizures occurring during or following neurosurgery. The product has an estimated market size of USD125 Million for the twelve months ending April 2015 according to IMS.
This is the 38th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-betalactam products. Aurobindo now has a total of 199 ANDA approvals (172 Final approvals including 9 from Aurolife Pharma LLC and 27 Tentative approvals) from USFDA.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.60 |
| Dr. Reddys Lab | 1237.20 |
| Cipla | 1235.85 |
| Zydus Lifesciences | 941.30 |
| Lupin | 2323.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: